Morgan Stanley maintains Clorox at Equal-Weight, raises price target to $94 from $87

What happened

Morgan Stanley kept Clorox at an Equal-Weight rating, meaning it expects performance broadly in line with the market, and raised its price target to $94 from $87. The new target is roughly in line with Clorox’s Nov. 3 closing price of $93.80.

Confirmed

Global impact / market context

The higher target signals a modestly improved view from Morgan Stanley, but its unchanged rating does not call for Clorox to outperform. Because the $94 target is close to the cited closing price, the note implies limited price difference at that reference point.

Analyst inference

Other recent analyst targets listed range from $80 to $99, with ratings including Underweight, Neutral, and Equal-Weight. That spread shows analysts differ on Clorox’s prospects; the article gives no earnings, sales, or cost data to explain their views.

Confirmed

What to watch

1. Compare future analyst target changes with Clorox’s reported closing price; a widening gap could indicate a changed view of expected share value, not a guaranteed outcome. Analyst inference
2. Watch for any rating change from Morgan Stanley, since its current Equal-Weight stance remains unchanged despite the higher target and would alter the note’s overall signal. Analyst inference
3. The article provides no company operating results or explanation for the target increase, so it does not establish whether sales, costs, or profits drove the revision. Confirmed

Evidence

• Original source link unavailable